Market Paradox: Nektar Therapeutics’ Legal Win Against Eli Lilly Fails to Ignite Investor Confidence

This past week, the biotechnology sector witnessed a rare and counterintuitive phenomenon: a significant courtroom victory that translated into a cold reception on Wall Street. Nektar Therapeutics (Nasdaq: NKTR) emerged from a three-year legal battle against pharmaceutical titan Eli Lilly (NYSE: LLY) with a $90 million jury verdict, yet the company’s share price struggled to maintain momentum, ultimately finishing the week essentially flat.

The verdict, delivered in the U.S. District Court for the Northern District of California, represents a landmark moment in the ongoing scrutiny of large-cap pharma’s treatment of smaller collaborative partners. However, for investors who had pinned their hopes on a much larger payout, the $90 million award—a fraction of the $1 billion in damages initially sought—has left the market in a state of cautious recalibration.

A Legal Battle Rooted in Collaboration

The dispute centers on a partnership forged in 2017. At the time, Nektar and Eli Lilly entered into a high-stakes agreement to co-develop rezpegaldesleukin (rezpeg), a novel therapeutic candidate initially aimed at treating autoimmune and chronic inflammatory conditions. The deal was valued at up to $400 million, including an initial $150 million upfront payment and $250 million in potential development and regulatory milestones.

However, the relationship deteriorated rapidly in early 2023. Following a failure of the Phase II ISLAND trial in systemic lupus erythematosus (SLE), Lilly moved to terminate the collaboration. Two months later, in a move that effectively ended the partnership, Lilly returned all global rights for the drug to Nektar.

Nektar responded in August 2023 by filing a lawsuit, alleging that Lilly had breached both the contract and the implied covenant of good faith and fair dealing. In its complaint, Nektar painted a picture of a "large pharmaceutical company elevating profits over all else," claiming that Lilly’s mismanagement of patient recruitment contributed to the failure of the lupus trial. Furthermore, Nektar alleged that Lilly manipulated and incorrectly calculated data from subsequent trials, an accusation Lilly has consistently denied while acknowledging certain calculation errors.

The Jury’s Verdict: A Half-Measure for Shareholders

The trial, presided over by Judge James Donato, culminated in a verdict that satisfied the legal requirements of the breach of implied covenant but fell significantly short of the financial windfall shareholders had anticipated.

In the immediate aftermath of the verdict, market volatility was palpable. Pre-market trading saw a brief surge of approximately 4.92%, as optimistic investors reacted to the news of a win. However, once the opening bell sounded on Friday, that sentiment evaporated. Shares slipped 4.6% from an opening price of $60, bottoming out at $57.22. By the close of the trading session, Nektar finished at $57.06, a 4% dip from Thursday’s closing price of $59.38.

Edward Nash, a managing director and senior biotechnology analyst at Canaccord Genuity, noted that the math simply didn’t align with market expectations. "A judgment of $90 million represents $2.64 in cash per share and would imply a 4.4% move upward in the stock compared to the previous closing price," Nash explained. The failure of the stock to hold these gains suggests that investors were pricing in a much higher settlement value.

The Silver Lining: Non-Dilutive Capital

Despite the disappointment regarding the quantum of the award, analysts are pointing toward a silver lining. Because the $90 million was not factored into the valuation models of most analysts—who were skeptical of the trial outcome—the payout represents a "non-dilutive capital addition" to Nektar’s balance sheet.

"The company did not require any monies from the case in order to continue developing their pipeline assets," Nash observed. "Therefore, any sum awarded represents an unexpected influx of cash that strengthens the company’s financial position without requiring the issuance of new shares."

However, the liquidity of this capital is currently theoretical. The verdict is subject to post-trial motions and an almost certain appeal from Eli Lilly. As legal experts point out, should Lilly exhaust the appeals process, it could be months, or even years, before Nektar sees a cent of the $90 million. Consequently, Canaccord Genuity has opted to exclude the payout from its immediate financial models, waiting for the money to be firmly in the bank before adjusting their valuation.

The Science of Rezpeg: A New Frontier in Immunology

While the legal drama captures headlines, the underlying science of rezpeg remains the true engine of Nektar’s long-term value proposition. Rezpeg is a first-in-class therapeutic designed to target the CD25 sub-receptor in the interleukin-2 (IL-2) receptor complex. By stimulating the proliferation of regulatory T cells (Tregs), the drug seeks to restore balance to the immune system—a stark contrast to traditional "inhibitor" drugs.

"Most drugs are inhibitors," said Dr. Jonathan Zalevsky, Nektar’s Chief R&D Officer. "Inhibitors work at the beginning, and then they get worse because biology always finds escape pathways. Rezpeg isn’t an inhibitor; it’s healing the immune system and allowing it to resolve inflammation naturally."

Recent data from the REZOLVE-AD trial (atopic dermatitis) supports this narrative. In August, findings published in The Lancet highlighted statistically significant, dose-dependent improvements in Eczema Area and Severity Index (EASI) scores. Notably, 71% of patients in the monthly dosing arm achieved EASI-75—a reduction in disease severity of at least 75%—with 63% maintaining a clear or almost-clear skin response after quarterly dosing.

Perhaps most promising is the durability of the response. Unlike conventional treatments, the benefits of rezpeg appear to outlast the drug’s pharmacokinetics, suggesting a potentially transformative impact for patients suffering from chronic, debilitating conditions. Nektar has confirmed it is now advancing rezpeg into pivotal studies for both atopic dermatitis and alopecia areata, with a Biologics License Application (BLA) for the former anticipated in 2029.

External Disruptions: The AI Factor

While Nektar wrestled with its legal affairs, the broader biotech sector faced a separate, high-tech disturbance. Anthropic, the AI powerhouse, announced that its Claude large-language model had autonomously discovered a novel enzyme system with properties reminiscent of CRISPR.

The announcement sent a ripple of anxiety through the gene editing market, with shares of various companies in the space dipping on Wednesday. While the immediate panic subsided, the incident highlighted the growing intersection of artificial intelligence and fundamental biological research.

Puneet Souda of Leerink Partners suggested that this development is a harbinger of a broader trend. "We see the need for automation and large-scale data growing rapidly," Souda noted. For investors in Nektar and similar biotech firms, the message is clear: while legal and clinical progress remains paramount, the entire landscape of drug discovery is being fundamentally reshaped by AI, potentially shifting the competitive dynamics of the industry overnight.

Implications and Outlook

The legal battle between Nektar and Eli Lilly serves as a cautionary tale of the risks inherent in pharmaceutical collaborations. When a partner as large as Lilly decides to shift its strategic focus—in this case, reportedly influenced by its $1.1 billion acquisition of Dermira and the subsequent success of the drug Ebglyss—smaller biotech firms are often left vulnerable.

Lilly, for its part, remains resolute. In a statement provided earlier this year, the company emphasized that its decision to terminate the collaboration was consistent with its internal portfolio review and was based on the competitive profile of the compound, including concerns over injection site reactions.

As Nektar moves forward, the focus will undoubtedly shift from the courtroom back to the clinic. The $90 million award, should it survive the appeals process, will provide a welcome buffer for the company’s ongoing research. However, the true test for Nektar will be its ability to commercialize rezpeg, a drug that the company believes could redefine the standard of care for autoimmune patients.

For the market, the lesson of the past week is twofold: legal victories in the pharmaceutical industry are rarely the clean-cut catalysts they appear to be, and the future of biotechnology is increasingly tied to the unpredictable, high-speed advancements of both clinical science and artificial intelligence. Whether Nektar can turn this legal win into long-term commercial success remains a narrative that will play out over the next several years.